The ability to use the extremely high KRAS mutation frequency in pancreatic cancer provided us with an important control to directly assess technical feasibility of cfDNA based molecular profiling of metastatic cancer patients where access to tumor tissue may problematic. The gene discussed is KRAS; the disease is neoplasm.